News from novartis A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

03:00 ET AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate...


Jul 25, 2019, 10:46 ET Falta de acesso ao exame de monitoramento para leucemia será avaliada pelo Governo

A Comissão Nacional de Incorporação de Tecnologias no SUS (Conitec) acaba de abrir uma consulta pública para avaliar a incorporação de exame que...


Jul 11, 2019, 13:00 ET Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions

The Know Now Testing Program, a Novartis initiative in collaboration with Quest Diagnostics, offers genetic mutation testing at no cost for all...


May 24, 2019, 13:21 ET AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

AveXis, a Novartis company, today announced innovative access programs for Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric...


May 16, 2019, 09:11 ET Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Novartis will present data from across its oncology portfolio at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology...


May 16, 2019, 07:30 ET Five nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives

Novartis today announced that five nonprofit organizations will receive a total of nearly $250,000 in funding through the company's STEP (Solutions...


May 11, 2019, 17:47 ET Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination

Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral...


Apr 15, 2019, 16:05 ET Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD

Novartis announced that the U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for brolucizumab...


Apr 01, 2019, 16:05 ET AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado

AveXis, a Novartis company, today announced it signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont,...


Mar 27, 2019, 00:40 ET Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of relapsing forms of...


Jan 08, 2019, 03:06 ET Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the...


Dec 08, 2018, 08:05 ET Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Novartis today announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali® (ribociclib) plus...


Dec 06, 2018, 10:35 ET Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

Novartis today announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL719...


Dec 01, 2018, 14:40 ET Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers

Novartis today announced longer-term analyses of both ELIANA and JULIET, the pivotal clinical trials of Kymriah (tisagenlecleucel) in children and...


Nov 16, 2018, 16:41 ET FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Novartis announced today that the US Food and Drug Administration (FDA) has expanded the label for Promacta® (eltrombopag) to include first-line...


Nov 14, 2018, 07:15 ET Novartis to fund five innovative ideas to support patients and the sickle cell community

Novartis announced the launch of the 2018 STEP (Solutions to Empower Patients) Program™ to inspire solutions that support people living with sickle...


Nov 11, 2018, 11:45 ET New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Novartis announced today results of the landmark PIONEER-HF trial showing that in-hospital initiation of Entresto tablets provided superior benefit...


Oct 29, 2018, 07:15 ET Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®

Novartis was awarded the 2018 Prix Galien USA Award for Best Biotechnology Product for Kymriah® (tisagenlecleucel) following its first-in-class...


Oct 27, 2018, 10:15 ET Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

Novartis announced additional brolucizumab Phase III results from year two that reaffirmed its positive year one findings. Brolucizumab met its...


Oct 22, 2018, 08:00 ET Novartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis

ovartis announced today new data showing Cosentyx® (secukinumab) delivered sustained ASAS response rates, a measure to evaluate improvements in the...


Oct 18, 2018, 17:26 ET Governo avalia a ampliação de tratamento para câncer renal

O câncer de rim é uma doença silenciosa, que não costuma apresentar sintomas em suas fases iniciais, fazendo com que muitos pacientes descubram o...


Oct 11, 2018, 17:07 ET Governo avalia a ampliação de tratamento para câncer renal

O câncer de rim é uma doença silenciosa, que não costuma apresentar sintomas em suas fases iniciais, fazendo com que muitos pacientes descubram o...


Oct 09, 2018, 16:53 ET Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study

Results from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab, a humanized anti-P-selectin monoclonal antibody being investigated...


Oct 08, 2018, 07:15 ET Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients

Novartis today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for investigational...


Aug 02, 2018, 07:00 ET Novartis announces US renewables agreement to reduce greenhouse gas emissions

Novartis announced today a Virtual Power Purchase Agreement (VPPA) in collaboration with Invenergy, North America's largest privately held renewable...